Status:
COMPLETED
Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter
Lead Sponsor:
Diakonhjemmet Hospital
Conditions:
Atrial Fibrillation
Atrial Flutter
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Atrial fibrillation is a condition in which the heart's upper chambers, the atria, contract at an abnormally rapid rate. It is a common type of arrhythmia, and occurs in 1-2% of the general population...
Eligibility Criteria
Inclusion
- Patients with paroxysmal atrial fibrillation/atrial flutter with duration \<48 hours
- Plasma potassium ≤4,0 mmol/L.
- Age ≥ 18 år
Exclusion
- Plasma potassium \> 4,0 mmol/L
- eGFR \<30 mL/min
- Patients on antiarrhythmic therapy (flecainid, amiodarone, dronedarone or sotalol)
- Pregnancy
- Breast feeding
- Patients participating in a clinical trial during the last six months
- Addison disease, adynamia episodic hereditary, or Sickle cell anemia
- Metabolic acidosis, pH \< 7,2
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
143 Patients enrolled
Trial Details
Trial ID
NCT01818583
Start Date
March 1 2013
End Date
November 1 2017
Last Update
July 31 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Diakonhjemmet Hospital
Oslo, Norway, 0370